Edwards Lifesciences (EW) Revenue (2009 - 2026)

Edwards Lifesciences has reported Revenue for 18 years, with the latest figure at $1.6 billion in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 16.7% year-over-year to $1.6 billion; the trailing twelve-month figure through Mar 2026 stood at $6.3 billion (up 14.15% YoY), and the FY2025 full-year result was $6.1 billion, up 11.55% from the prior year.
• Revenue for Q1 2026 stood at $1.6 billion, up from $1.6 billion in the prior quarter.
• The five-year high for Revenue was $1.6 billion in Q1 2026, with the low at $429.9 million in Q4 2022.
• Average Revenue over 5 years is $1.3 billion, with a median of $1.4 billion recorded in 2024.
• Year-over-year, Revenue plunged 67.67% in 2022 and soared 194.58% in 2023.
• Tracing EW's Revenue over 5 years: stood at $429.9 million in 2022, then soared by 194.58% to $1.3 billion in 2023, then grew by 9.43% to $1.4 billion in 2024, then advanced by 13.26% to $1.6 billion in 2025, then rose by 5.03% to $1.6 billion in 2026.
• The last three Revenue figures came in at $1.6 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.

Peer Comparison